AURA BIOPHARM ANNOUNCES THE GRANT OF A US PATENT COVERING TREATMENT AND PREVENTION OF APS WITH AUR-1001
Aura Biopharm has announced the the US Patent office has granted a patent covering the treatment and prevention of APS with its molecule AUR-1101. The patent US61/844,505 was granted in July 2017.
AUR-1101 is an anti Beta2 GP1 monoclonal antibody which represents a first-in-class treatment for antiphospolipid syndrome (Hughes syndrome), an autoimmune disease with multiple clinical manifestations, highly invalidating and deadly and with no specific available treatment. AUR-1001 is the lead program of the company and is available for licensing and co-development.
Olav Flaten, CEO of Aura Biopharm commented:
“The grant of the US patent for AUR-1001 is an important milestone in the development of this molecule which certifies the high quality and innovative aspects of the research program that lead to its identification and characterization. This patent strengthen the position of the company in the search of funding and partners to develop this first-in-class molecule for the treatment and prevention of APS”
Aura Biopharm is a company that looks for new licensing opportunities of molecules with potential therapeutic activity in a variety of diseases such as autoimmune and orphan diseases with unmet medical needs. These in-licensing molecules are then partly developed by the company preferably in collaboration with other partners and then out-licensed to larger biothec/pharmaceutical companies to complete their development program. Recently founded AURA Biopharm is developing a treatment for a serious rare autoimmune disease, Antiphospholipid Syndrome. Based in Oslo, but operating virtually and led by an International team of very experienced scientists, managers and experts, AURA Biopharm has developed an exciting collaborative business model with great possibilities to deliver future breakthrough therapies to the market.